Indications for Basic Screening Panel in Adults
Order a basic screening panel (CBC with differential, CMP, fasting lipid profile, fasting glucose or HbA1c, urinalysis) for all adults beginning at age 35-40 years, with earlier screening for those with cardiovascular risk factors, and repeat every 1-3 years based on initial results and risk profile. 1
Age-Based Screening Thresholds
Start at age 35-40 years for general population:
- Men ≥40 years and women ≥50 years (or postmenopausal) should undergo comprehensive lipid screening 2
- Diabetes screening should begin at age 35 years for all adults 1
- Blood pressure measurement should be performed at every clinical encounter 3
Risk Factor-Based Screening (Screen at ANY Age if Present)
Screen immediately regardless of age if the patient has:
Cardiovascular Risk Factors 2, 3, 1
- Current cigarette smoking
- Family history of premature CVD (men <55 years, women <65 years in first-degree relatives)
- Hypertension (≥140/90 mmHg or on antihypertensive therapy)
- Clinical evidence of atherosclerosis or erectile dysfunction
- Chronic kidney disease or inflammatory disease
Metabolic Risk Factors 1, 4
- Overweight/obesity (BMI ≥25 kg/m² or ≥23 kg/m² in Asian Americans) with any additional risk factor:
- First-degree relative with diabetes
- High-risk race/ethnicity (African American, Latino, Native American, Asian American, Pacific Islander)
- HDL cholesterol <35 mg/dL or triglycerides >250 mg/dL
- Physical inactivity
- Polycystic ovary syndrome
- History of gestational diabetes
- Conditions associated with insulin resistance (severe obesity, acanthosis nigricans)
Special Populations 5, 6
- HIV-infected individuals (require CBC, CMP, fasting glucose/HbA1c, fasting lipids at entry into care)
- Patients with established diabetes (annual comprehensive panel including lipids, liver function, urinary albumin-to-creatinine ratio, serum creatinine with eGFR) 5, 7
Specific Test Components and Rationale
Complete Blood Count with Differential 6
- Detects anemia, leukopenia, thrombocytopenia common in chronic disease
- Baseline before initiating medications with myelosuppressive effects
- Required for calculating total CD4 count in specific populations
Comprehensive Metabolic Panel 3, 6
Essential components:
- Fasting glucose or HbA1c for diabetes screening
- Serum creatinine with eGFR for kidney function
- Electrolytes (sodium, potassium, calcium)
- Liver function tests (ALT, AST, bilirubin, albumin) 8
- Thyroid-stimulating hormone 3
Common pitfall: The comprehensive metabolic profile has limited value as a general screening tool in truly asymptomatic populations without risk factors 9, but becomes highly relevant when specific risk factors are present.
Fasting Lipid Profile 2, 10
Includes: Total cholesterol, LDL, HDL, triglycerides, calculated non-HDL cholesterol
- Non-fasting samples are acceptable for initial screening in most cases 11
- Fasting required only if non-fasting triglycerides >440 mg/dL (5 mmol/L) 11
- Flag abnormal values: triglycerides ≥175 mg/dL (non-fasting), LDL ≥115 mg/dL, HDL ≤40 mg/dL 11
Glucose Testing 1, 12
Either fasting glucose OR HbA1c is acceptable:
- Fasting plasma glucose: prediabetes 100-125 mg/dL, diabetes ≥126 mg/dL
- HbA1c: prediabetes 5.7-6.4%, diabetes ≥6.5%
- HbA1c offers convenience (no fasting required) but may be unreliable in conditions with altered red blood cell turnover 12
Urinalysis 3
- Basic screening for kidney disease, proteinuria
- Consider urinary albumin-to-creatinine ratio if eGFR <60, hypertension, or diabetes present 2
High-Sensitivity C-Reactive Protein (hs-CRP)
hs-CRP is NOT routinely recommended for general screening panels. While it predicts cardiovascular risk and correlates with disease severity 13, major guidelines do not include it in standard screening protocols 5, 2, 3. Reserve hs-CRP for:
- Intermediate-risk patients where additional risk stratification would change management
- Patients with unexplained symptoms suggesting inflammatory conditions
Screening Intervals
Repeat testing frequency: 1, 10
- Every 3 years minimum if initial results normal and low risk
- Annually if Framingham Risk Score ≥5% or prediabetes present
- More frequently if lipid levels near treatment thresholds or multiple risk factors present
- Patients with established diabetes require annual comprehensive evaluation 5, 7
Key Clinical Caveats
Avoid these common errors:
- Don't screen asymptomatic low-risk individuals under age 35 without specific indications—yield is extremely low 9
- Don't rely solely on age cutoffs for minority populations—they develop diabetes at younger ages and lower BMI thresholds 14
- Don't assume fasting is always required—non-fasting lipids are acceptable for initial screening 11
- Don't order hs-CRP routinely—it's not part of standard screening panels despite its prognostic value 5, 2, 3
The 2015 USPSTF diabetes screening criteria (age 40-70 + overweight/obese) miss approximately 50% of dysglycemia cases, particularly in racial/ethnic minorities 14. Therefore, use the more inclusive age 35+ threshold with risk factor assessment 1.